Dr. Reddy's Laboratories Ltd. closed 16.92% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr. Reddy's Laboratories Ltd. 500124 shares slipped 2.23% to 1,197.40 Indian rupees Monday, on what proved to be an ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a prominent stock. Explore the latest information on Dr Reddys, including: ...

Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Dr. Reddy's shares in Friday's trade saw a sharp fall following the company's weak set of earnings for the December quarter.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) is expected to be announcing its earnings results on Wednesday, January ...

Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The ...